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Abstract 
Background 
Non-prescription medicines can be misused, abused or lead to dependence but the 
prevalence of these problems within the UK general population was unknown. The aim of 
this study was to estimate the prevalence of self-reported misuse, abuse and dependence to 
non-prescription medicines (NPMs). 
Methods 
A cross-sectional postal survey was sent to 1000 individuals aged ≥18 years randomly 
drawn from the UK Edited Electoral Register. 
Results 
A response rate of 43.4% was achieved. The lifetime prevalence of NPM misuse was 19.3%. 
Lifetime prevalence of abuse was 4.1%. Younger age, having a long-standing illness 
requiring regular NPM use and ever having used illicit drugs or legal highs were predictive of 
misuse/abuse of NPMs. In terms of dependence, lifetime prevalence was 2% with 0.8% 
currently dependent and 1.3% dependent in the past. Dependence was reported with 
analgesics (with and without codeine), sleep aids and nicotine products. 
Conclusion 
Given the increasing emphasis on self-care and empowering the public to manage their 
health with NPMs, the findings highlight the need for improved pharmacovigilance of these 
medicines to maximise benefits with minimal risk. Health care providers need to be aware of 
the potential for misuse, abuse and dependence, particularly in patients with long-term 
illness. 
INTRODUCTION 
Non-prescription medicines (NPMs), also known as over-the-counter (OTC) medicines, are 
used for the management of minor ailments. They are convenient for consumers and can be 
obtained from community pharmacies and other retail outlets e.g. petrol stations and 
supermarkets. NPMs facilitate self-care which brings about benefits for both the individual 
and the National Health System (NHS) by reducing the burden on other healthcare 
settings.1, 2 A recent study estimated that 13% and 5% of general practice and emergency 
department (ED) consultations, respectively, were for minor ailments suitable for 
management in community pharmacies.3 Symptom resolution was shown to be similar for 
minor ailments irrespective of setting whilst overall costs are significantly lower for pharmacy 
consultations compared with general practice and ED consultations.4 In 2007, there were an 
estimated 57 million GP consultations per year for minor ailments at a total cost of £2 billion 
to the NHS.5 
Whilst NPMs are often perceived by the public as being safer than prescription medicines,6 
they can cause harm. NPMs have the potential to be misused, abused and lead to 
dependence.7 Specific NPMs most frequently associated with dependence are those 
capable of causing tolerance and withdrawal e.g. codeine-containing analgesics and 
smoking cessation products containing nicotine.8-10 However, the psychological aspects of 
addiction may occur with any substance, including NPMs.11 There are other harms 
associated with NPM including direct physiological or psychological harm, harm from 
another ingredient and associated social and economic problems.7 Codeine-containing 
analgesics are commonly associated with abuse and dependence due to the properties of 
codeine with studies highlighting the morbidity caused by their additional ingredients, i.e. 
paracetamol or ibuprofen.12 In response to these harms, regulation has been applied in the 
UK to minimise the risk of harm. This includes restricted indications, limits on pack size, and 
warnings on packets, patient information leaflets and advertisements.13 Codeine containing 
products contain an additional specific warning about the risk of addiction. 
Despite the drive to encourage and enable self-care in the UK, 1, 2, 14-16 there is minimal 
information about the prevalence of NPM misuse, abuse and dependence in the general 
population. Much of the existing research focuses on pharmacists’ perceptions of 
prevalence.17-21 Patient reported behaviour tends to be highly specific in terms of the 
population or the outcome measured e.g. misuse of NPMs in community dwelling older 
adults and in people with HIV.22, 23 Interviews with members of the general public in Northern 
Ireland found that almost a third of respondents (n=298) had personally encountered OTC 
abuse, although this included personal experience, knowledge or observation, and was 
solely in relation to abuse.24 
The current study was designed to estimate the prevalence of and factors associated with 
self-reported NPM misuse, abuse and dependence in the general UK population. For the 
purpose of this study, NPM misuse was defined as the use of an NPM for a legitimate 
medical purpose, but in an incorrect manner, e.g. in terms of dosage or duration of use.18, 25, 
26 Abuse was defined as use for a non-medical purpose, e.g. to achieve mind-altering effects 
or weight loss.18, 25, 26 Dependence and addiction were defined as “the repeated use of a 
non-prescription medicine in which the person has a need or desire to use the non-
prescription medicine and has difficulty in voluntarily stopping or altering their use”.27 
METHODS 
Study design and participants 
This was a cross-sectional postal survey of a random sample of 1000 individuals aged 18 
years and older drawn from the UK Edited Electoral Register.  
Questionnaire Development 
Questionnaire development was informed by the literature, including previous surveys,28, 29 
and discussion with researchers with expertise in this area. The terms “misuse” and “abuse” 
were not used in the questionnaire to avoid potential stigmatisation and to reduce the 
likelihood of social desirability and responder bias. Instead, respondents were asked to 
indicate if they had ever knowingly used NPMs in specific ways e.g. “for a reason that was 
not recommended by the manufacturer e.g. for the feeling or effect it caused” (i.e. abuse) or 
“at a higher dose than recommended by the manufacturer” (i.e. misuse). The definition of 
dependence and addiction (above) was provided at the beginning of the relevant section. 
Pre-piloting and piloting 
Pre-piloting was conducted with an opportunistic sample of 23 academic staff and students. 
All were asked to complete the questionnaire and provide feedback on clarity and ease of 
completion. The questionnaire was also reviewed by the Project Director of Over-Count 
Drugs Information Agency (http://over-count.weebly.com/), a voluntary organisation which 
provides a telephone helpline and online discussion forum for people dependent on NPMs. 
Formal piloting tested both the distribution process and phrasing of the questionnaire. A 
cover letter, questionnaire, feedback form and reply-paid envelope were posted to a random 
sample of 100 individuals from the Edited Electoral Register. A pre-notification letter and 
reminder were used. Questionnaires were returned by 42 of the 100 addressees. Completed 
questionnaires were examined to identify problems. A list was compiled of feedback from 
participants and problems identified by examining the completed questionnaires; this 
informed the refinement of the final questionnaire. 
Procedures 
In August 2013, a pre-notification letter (to enhance response rate30) was sent to a random 
sample of 1000 individuals aged ≥18 years from the UK Edited Electoral Register (provided 
by an independent commercial marketing company) to notify them of the survey. Two weeks 
later, addressees were sent a cover letter, questionnaire and reply paid envelope. 
Reminders were sent to non-responders at two and four weeks. Reminder letters included a 
questionnaire and reply-paid envelope. 
Data management and analysis 
Data were entered and analysed using SPSS (Version 22). An independent quality 
assurance check was conducted on data entry by a research secretary for 10% of 
questionnaires; these were selected using a random sequence generator. 
Sample size 
An estimated prevalence of 15% for misuse and abuse, and 5% for dependence, was used 
for the sample size calculation for the current study based on earlier estimates8, 10, 22, 23, 31; 
however these studies were restrictive in terms of their populations, the NPMs of interest 
and the type of inappropriate use measured. A respondent group of 300 was required to 
detect a 5% prevalence of dependence with 2.5% precision (95% Confidence Interval (CI) 
2.5% to 7.5%) and a 15% prevalence of misuse with 4% precision (95% CI 11.0% to 19.0%). 
A minimum expected response rate of 30% (n=300) implied this needed to be inflated to an 
overall sample of 1000. 
Statistical methods 
Chi-squared tests compared respondents’ sex and country of residence with those of non-
respondents. A Mann-Whitney U test was used to compare the distribution of year of birth as 
the data for this variable were not normally distributed. Chi-squared tests compared 
respondents’ age, sex, ethnicity, partnership status and general health with data from the 
2011 UK Census to determine the representativeness of respondents compared to the 
general population.  
Chi-squared tests were used to examine univariate associations between categorical 
characteristics and misuse/abuse status. An independent samples t-test was used for age as 
the data were roughly normally distributed. Significant associations (p<0.05) were entered 
into a binary logistic regression model using the enter method to produce unadjusted ORs 
and 95% CIs to determine which characteristics were independently related to self-reported 
misuse/abuse of NPMs. 
Preliminary basic descriptive analysis was undertaken on the full dataset. Where possible 
and logical and without distortion of findings, aggregations were made in order to ensure 
sufficient numbers for analysis and allow comparison with national data. 
RESULTS 
Participants 
The overall response rate was 43.4% (411/946) (Figure 1 for electronic version).The pre-
notification letter was sent to 1000 addressees. Fifty-four addressees were excluded from 
the denominator due to death, change of address or asking to be excluded from the 
research prior to receiving the questionnaire. 
(Figure 1 for electronic version) 
Descriptive data 
Respondents’ age ranged from 19 to 92 years (mean=60, SD=15.5). Respondents were 
similar to national data in terms of gender (χ2=0.026, df=1, p=0.87) but not age, country, 
partnership status, ethnicity or general health (all p<0.001) (Table 1).32 
(Table 1 Characteristics of survey respondents) 
No association was found between response status and country of residence (i.e. England, 
N. Ireland, Scotland or Wales) (χ2=5.3, df=3, p=0.15) or gender (χ2=0.002, df=1, p=0.96). 
Respondents were significantly older than non-respondents by 10 years (Mann-Whitney U = 
86244.0, p<0.001). 
The majority of respondents who used NPMs indicated that they always read the directions 
for use when using a NPM that they have never used before (214/343) and follow the 
directions for use (243/349) (Table 2). 
(Table 2 Prevalence of self-reported non-prescription medicine abuse and misuse) 
Non-prescription medicine misuse 
The lifetime prevalence of any type of self-reported NPM misuse was 19.3% (n=76, 95% CI 
15.7 to 23.5%): 11.9% (n=47, 95% CI 9.1 to 15.5%) for using a higher dose than 
recommended, 10.6% (n=42, 95% CI 8.0 to 14.1%) for using more often than recommended 
and 10.6% (n=42, 95% CI 7.9 to 14.0%) for using for a longer time than recommended 
(Table 2). Analgesics, with and without codeine, were the most frequently misused products 
(Table 1 for electronic version). 
(Table 1 for electronic version - Categories of non-prescription medicines misused/abused 
and frequency of misuse/abuse) 
Non-prescription medicine abuse 
The lifetime prevalence of self-reported abuse was 4.1% (n=16, 95% CI 2.5 to 6.5%) (Table 
2). The most common reason for abusing a NPM was for sleep or relaxation purposes. 
Medicines used for these purposes were: cold and flu products containing sedative 
antihistamines (n=3), cough remedies (n=2), codeine-containing analgesics (n=2), 
analgesics without codeine (n=1) and an antihistamine (n=1). A cough remedy was also 
used by one respondent for another reason: “When trying to conceive, I read that Benylin 
help make women more likely to conceive as it made secretions more receptive to sperm”. 
Haemorrhoid products were reportedly used for facial skin-care purposes (n=2), and sore 
throat products were used for the pleasant taste (n=1) (Table 1 for electronic version). 
Characteristics associated with self-reported misuse/abuse 
Respondent characteristics associated (p<0.05) with misuse/abuse were: age; partnership 
status; level of education; employment status; presence of a long-standing illness, disability 
or infirmity which requires the regular use of a NPM; and ever having used illegal drugs or 
legal highs (hereinafter referred to as illicit drug use) (Table 3). When entered into a logistic 
regression model, these characteristics correctly predicted 18.1% (15/83) of individuals who 
had abused/misused NPMs and 95.3% (264/277) who had not abused/missed NPMs. 
Characteristics that remained significant independent predictors of misuse/abuse were age, 
presence of a long-standing illness requiring regular NPM use and illicit drug use status 
(Table 3).  
(Table 3 Characteristics associated with non-prescription medicine misuse/abuse and 
summary of logistic regression model analysis for variables predicting misuse/abuse) 
Non-prescription medicine dependence 
Most respondents (71.3%, 281/394) were aware of the potential for NPMs to cause 
dependence or addiction (Table 4). In total, 12% (47/396) of respondents indicated that they 
personally knew at least one person (including family members, friends and colleagues) who 
had been dependent on or addicted to a NPM. The NPMs associated with dependency or 
addiction in these people were: analgesics (without codeine (n=14), with codeine (n=13), 
unspecified (n=7)), smoking cessations products (n=4), laxatives (n=3), sleep aids (n=3), 
cough remedies (n=2), caffeine tablets (n=2), and decongestants (n=1). 
(Table 4 Dependence to non-prescription medicines) 
The lifetime prevalence of NPM dependence was 2% (n=8, 95% CI 1.0 to 3.9%); 0.8% (n=3, 
95% CI 0.3 to 2.2%) were currently dependent whilst 1.3% (n=5, 95% CI 0.5 to 2.9%) had 
been dependent in the past. For those who had ever been dependent, analgesics containing 
codeine (n=4), analgesics without codeine (n=1), a herbal sleep aid (n=1) and nicotine gum 
(n=1) were the NPMs of dependence. One individual did not provide a response but their 
other data implied dependence associated with analgesic use. 
Of the eight respondents ever dependent, six obtained their NPM of dependence from a 
pharmacy: five used multiple pharmacies and one used one pharmacy. No respondents 
obtained the NPM of dependence via the internet. Most dependent individuals were rarely or 
never questioned by pharmacy staff about their medicine needs or health condition when 
purchasing the NPM of dependence (Table 4). The individual indicating that they were 
‘usually’ questioned by pharmacy staff was dependent on a codeine-containing analgesic. 
Those ‘rarely’ questioned were dependent on a codeine-containing analgesic (n=1), a 
smoking cessation product (n=1) and an herbal sleep aid (n=1). The two respondents who 
were ‘never’ questioned were dependent on codeine-containing analgesics. No respondents 
had ever been refused the sale of the NPM of dependence, or had ever been referred to a 
GP or substance misuse clinic, by a member of pharmacy staff. 
The eight respondents who reported ever being dependent on or addicted to a NPM were 
asked where they had sought help for their dependence or addiction. The three individuals 
currently dependent selected ‘Nowhere – I haven’t sought help’. Of the five whose 
dependence was in the past, two had not sought help, two sought help from a GP, and one 
from family and friends. 
DISCUSSION 
Main findings of this study 
This is the first study to estimate the prevalence of NPM misuse, abuse and dependence in 
the UK general population. Lifetime prevalence of any type of misuse was 19.3%. Lifetime 
prevalence of abuse and dependence was 4.1% and 2%, respectively. The products most 
commonly misused and abused were codeine containing analgesics, and cough and cold 
remedies. Dependence was reported with analgesics (with and without codeine), sleep aids 
and nicotine products. Being younger, having a long-standing illness requiring regular use of 
NPMs and ever having used illicit drugs were predictive of misuse or abuse of NPMs. 
What is already known on this topic 
There is a drive to encourage and enable self-care in the UK through the use of NPMs for 
minor ailments. Pharmacy customers who make direct product requests by name are less 
likely to be questioned by pharmacy staff than customers/patients seeking advice regarding 
the management of conditions or symptoms.33 Furthermore, pharmacy users generally 
report low rates of information disclosure to pharmacy personnel during consultations for 
NPMs.28 From a pharmacy perspective, pharmacists suspect that NPMs are sometimes 
misused.20 Research has also demonstrated that NPMs can be misused, abused or lead to 
dependence for some people.7  
The prevalence of these problems within the UK general population was unknown. Previous 
surveys have been conducted but these were limited in either the population studied or type 
of NPM studied. 
What this study adds 
This study identified potential predictors of misuse/abuse as: being of younger age, having a 
long-standing illness which requires regular NPM use, and use of illicit drugs. Having a long-
standing illness is clinically relevant as it reinforces the need for clinicians to be aware of 
concurrent use of NPMs by their patients, particularly those with pain, and to be mindful of 
the potential for misuse, abuse and dependence. 
Most individuals ever dependent on an NPM had not sought formal help for their 
dependence. The reasons for this are unknown. Previous qualitative research involving 
individuals with non-prescription codeine dependence found that attempts at self-treatment 
were often ineffective9; consequently there is a need for future research to identify the 
barriers and enablers to seeking treatment for NPM dependence. A qualitative study is on-
going by the research team to address this. There may be a need to clarify sources of 
treatment/support for NPM dependence and raise awareness of these treatment options. 
In our study, individuals who were or had been dependent, were generally rarely or never 
questioned by pharmacy staff about their purchase. More active engagement may be 
needed by both pharmacy personnel and patients/customers during these consultations, 
particularly when requests are made for NPMs associated with misuse, abuse and 
dependence, to explore the need for referral to an appropriate source of support/treatment. 
However, previous research indicates that there may be difficulties with this due to the 
difficulty some pharmacists have in challenging customers or raising their concerns with 
customers, as well as their lack of confidence about signposting customers to potential 
sources of support.34 
Respondents’ acknowledgement of the potential for NPMs to lead to dependence was high 
and suggests that there is public awareness that NPMs are associated with risks. However, 
a considerable proportion of individuals do not always read the directions for use and 
therefore alternative, or additional, methods of providing important information on medicine 
risk should be considered, e.g. by pharmacy staff at the time of purchase, through product 
advertisements or mass media campaigns.  
The survey achieved a higher than anticipated response compared with recent studies using 
the same sampling method.28, 35 The survey was inclusive with regard to NPMs and was not 
restricted to a limited selection of NPMs as in previous research. Furthermore it was 
conducted on a large, national sample, unlike previous research. 
Limitations of this study 
There may be some response bias given that respondents differed from non-respondents in 
various ways; they were older and more likely to be: white, married, in a civil partnership or 
widowed; rate their general health as poorer and reside in Scotland or Wales.32 A US study 
indicated that the lifetime prevalence of abuse of non-prescription cough and cold medicines 
is higher in younger individuals therefore the prevalence of lifetime abuse may be 
underestimated.36 The same US study reported that lifetime use of a non-prescription cough 
or cold medicine “to get high” was 3.0% and 6.6% amongst those aged 12-17 and 18-25 
years, respectively, whilst the lowest prevalence rates were among those aged 50-64 years 
and 65 years and older, respectively. Consequently, the older age of respondents in our 
study and the exclusion of individuals less than 18 years of age may have underestimated 
the prevalence of abuse in our study. Similarly, groups that are less likely to have registered 
to vote or to have opted out of the Edited Electoral Register will be under-represented which 
may have affected the results in unknown ways. Other factors may also serve to under- or 
over-estimate the prevalence of misuse, abuse and dependence. Social desirability bias and 
recall bias may result in under-reporting. The explicit use of the terms “dependence” and 
“addiction” may have resulted in under-reporting of dependence due to social desirability 
bias, although the researchers attempted to minimise the likelihood of this for misuse and 
abuse by avoiding the use of these terms in the questionnaire. The finding that younger age 
was predictive of lifetime misuse or abuse of NPMs may be due to recency; it may be that 
older individuals had simply forgotten about previous use. People may have unknowingly 
misused NPMs. Our study found that 38% of respondents who used NPMs did not always 
read the directions for use when using a NPM that they have never used before, which was 
higher than shown previously.37 
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Table 1 Characteristics of respondents 
  Survey 
respondentsa 
National 
datab 
  % (n) %  
Country England 78.6 (323) 83.9 * 
(N=411) Northern Ireland 1.0 (4) 2.9  
 Scotland 13.4 (55) 8.4  
 Wales 7.1 (29) 4.8  
Sex Female 50.4 (204) 50.9  
(N=405) Male 49.6 (201) 49.1  
Age range (in years) 20-29 6.5 (26) 17.9 * 
(N=398c) 30-39 4.3 (17) 17.3  
 40-49 10.6 (42) 19.3  
 50-59 19.8 (79) 16.0  
 60-69 29.9 (119) 14.2  
 70-79 20.4 (81) 9.3  
 80+ 8.5 (34) 6.0  
Ethnicity White 97.3 (390) 87.2 * 
(N=401) Other 2.7 (11) 12.8  
Partnership status Never married or in civil partnership 19.0 (76) 34.7 * 
(N=400) Married or in civil partnership 61.5 (264) 46.7  
 Separated or divorced 8.3 (33) 11.6  
 Widowed 11.3 (45) 7.0  
General health Very good/Good 70.8 (286) 81.2 * 
(N=404) Fair 23.3 (94) 13.2  
 Bad/Very Bad 5.9 (24) 5.6  
Long-standing illness requiring regular use of NPMs Yes 17.4 (69)   
(N=397) No 82.6 (328)   
Education (highest level completed) No formal qualification 14.0 (56)   
(N=401) High school or secondary school 42.6 (171)   
 College 28.7 (115)   
 University degree 14.7 (59)   
Employment status Employed 38.3 (152)   
(N=397) Self-employed 7.6 (30)   
 Retired 43.8 (174)   
 Otherd 10.3 (41)   
Alcohol drinker Yes 74.3 (297)   
(N=400) No 25.8 (103)   
Smoking status Smoker 11.4 (46)   
(N=402) Ex-smoker 39.6 (159)   
 Never smoked 49.0 (197)   
Ever used drugs or legal highs Yes 7.7 (31)   
(N=402) No 92.3 (371)   
NPMs: non-prescription medicines. 
a Not all of the 411 respondents gave a valid response to every question. Actual numbers of respondents are 
shown next to the individual questions. Results show valid percentages. 
b Office for National Statistics 2011. 
c One respondent under 20 years of age was excluded to allow direct comparison between survey data and 
national data. 
d Comprises: full-time student, looking after home/family, long-term sick or disabled, unemployed and 
available for work, and other. 
* p<0.001.
Table 2 Prevalence of self-reported non-prescription medicine abuse and misuse  
 % (n) 
Have you ever knowingly used a non-prescription medicine:   
For a reason that was not recommended by the manufacturer e.g. for the feeling   
or effect it caused?a Yes – in the past month 0.8 (3) 
(N=394) Yes – more than a month ago 3.3 (13) 
No – never 95.9 (378) 
At a higher dose than recommended by the manufacturer?b  
(N=394) Yes – in the past month 2.5 (10) 
Yes – more than a month ago 9.4 (37) 
No – never 88.1 (347) 
More often than recommended by the manufacturer?b  
(N=395) Yes – in the past month 2.8 (11) 
Yes – more than a month ago 7.8 (31) 
No – never 89.4 (353) 
For a longer time than recommended by the manufacturer?b  
(N=396) Yes – in the past month 2.3 (9) 
Yes – more than a month ago 8.3 (33) 
No – never 89.4 (354) 
Any type of misuse   
(N=393) Yes – in the past month 4.6 (19) 
Yes – more than a month ago 13.9 (57) 
No – never 77.1 (317) 
When using a non-prescription medicine that I have never used before, I read the directions for use. 
(N=343)* Never 0.9 (3) 
Rarely 4.4 (15) 
Sometimes 7.6 (26) 
Usually 24.8 (85) 
Always 62.4 (214) 
When using non-prescription medicines myself, I follow the directions for use. 
(N=349)* Never 0.9 (3) 
Rarely 0.9 (3) 
Sometimes 4.9 (17) 
Usually 23.8 (83) 
Always 69.6 (243) 
*Respondents who indicated earlier in the questionnaire that they never use non-prescription medicines 
(n=28) were instructed to skip this question. 
a abuse; b misuse. 
Table 3 Characteristics associated with non-prescription medicine misuse/abuse and summary of logistic 
regression model analysis for variables predicting misuse/abuse 
  Ever misused 
or abused 
Never misused 
or abused    
  % % p-value OR 95% CI 
Sex    0.27   
(N=388) Female 55.8 48.3  - - 
 Male 44.2 51.7  n/a n/a 
Age (in years)    <0.001   
(N=383) Mean (SD) 51.2 (14.8) 62.1 (14.6)  1.05 1.02-1.08 
Ethnicity    1.0   
(N=386) White 97.6 97.3  - - 
 Other 2.4 2.7  n/a n/a 
Partnership status     0.001   
(N=383) Never married or in civil partnership 30.6 15.8  - - 
 Married or in civil partnership 51.8 65.8  1.52 0.36-6.40 
 Separated or divorced 12.9 6.7  1.04 0.31-3.43 
 Widowed 4.7 1.7  0.52 0.12-2.15 
General health    0.84   
(N=387) Very good 24.4 24.3  - - 
 Good 45.3 47.5  n/a n/a 
 Fair, bad or very Bad 30.2 28.2  n/a n/a 
Long-standing illness requiring regular use of NPMs   <0.001   
(N=381) Yes 30.6 13.5  - - 
 No 69.4 86.5  0.33 0.18-0.62 
Education (highest level completed)   0.014   
(N=385) No formal qualification 7.0 15.1  - - 
 High school or secondary school 36.0 45.2  0.80 0.25-2.61 
 College 40.7 25.4  0.84 0.37-1.91 
 University degree 16.3 14.4  0.52 0.23-1.18 
Employment    0.002   
(N=381) Employed or self-employed  61.2 43.2  - - 
 Retired 25.9 47.6  0.83 0.36-1.92 
 Other 12.9 9.1  0.78 0.27-2.26 
Alcohol drinker   0.28   
(N=384) Yes 80.2 73.8  - - 
 No 19.8 26.2  n/a n/a 
Smoking status    0.25   
(N=386) Smoker 15.1 10.0  - - 
 Ex-smoker 33.7 41.7  n/a n/a 
 Never smoked 51.2 48.3  n/a n/a 
Ever used drugs or legal highs   <0.001   
(N=385) Yes 18.6 4.7  - - 
 No 81.4 95.3  0.35 0.15-0.85 
NPMs: non-prescription medicines. 
n/a = Not significant at the univariate level, hence not included in the model. 
Table 4 Dependence to non-prescription medicines 
  % (n) 
Some NPMs may cause dependence or addiction 
(N=394) Strongly disagree 4.1 (16) 
 Disagree 6.1 (24) 
 Neither 18.5 (73) 
 Agree 26.9 (106) 
 Strongly agree 44.4 (175) 
Do you personally know someone who has been dependent on or addicted to any NPMs? 
(N=396) Yes 11.9 (47) 
 No 88.1 (349) 
Have you ever considered yourself to be dependent on or addicted to any NPMs? 
(N=397) Yes – in the past month 0.8 (3) 
 Yes – more than a month ago 1.3 (5) 
 No - never 98.0 (389) 
From where have you obtained the NPM?*   
(N=8) A pharmacy  (6) 
 A shop without a pharmacy  (2) 
 Friends or family  (1) 
 Other  (2) 
Were you asked about your medicine needs or health condition by a member of pharmacy staff when  
buying the NPM? Always  (0) 
(N=6) Usually  (1) 
 Sometimes  (0) 
 Rarely  (3) 
 Never  (2) 
What were you asked about when buying the NPM?*   
(N=4) Whether you had used it before?  (3) 
 Who was it for?  (3) 
 How often were you using it?  (2) 
 Whether you were using any other medicines?  (2) 
NPM: non-prescription medicine. 
*Frequencies total more than denominator as multiple response options were allowed. 
 
